Gefitinib for recurrent non-small-cell lung cancer: All things are not created equal

被引:2
作者
Dahlberg, Suzanne E. [1 ]
Gray, Robert J. [1 ]
Johnson, Bruce E. [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.2008.17.0837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:4233 / 4235
页数:3
相关论文
共 12 条
[11]   Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J].
Thatcher, N ;
Chang, A ;
Parikh, P ;
Pereira, JR ;
Ciuleanu, T ;
von Pawel, J ;
Thongprasert, S ;
Tan, EH ;
Pemberton, K ;
Archer, V ;
Carroll, K .
LANCET, 2005, 366 (9496) :1527-1537
[12]   Planned equivalence or noninferiority trials versus unplanned noninferiority claims: Are they equal? [J].
Zee, BCY .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1026-1028